Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Microbial Products Market Research Report Information By Type (Enzymes, Polysaccharides, Nutrients, Chemotherapeutic Agents, Antibiotics, and Vaccines), By Source (Bacterial, Viral, and Fungi), By Applications (Pharmaceutical Diagnostic, and Biotechnology), By End-Users (Pharmaceutical Industries, Biotechnological Industries, Hospitals and Clinics, Diagnostic Labs, Research, and Academics), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

ID: MRFR/LS/0281-HCR | 139 Pages | Author: Kinjoll Dey| May 2024

Global Microbial Products Market Overview

Microbial Products Market Size was valued at USD 1.59 Billion in 2023. The Microbial Products market industry is projected to grow from USD 1.69 Billion in 2024 to USD 2.58 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.44% during the forecast period (2024 - 2032). Increasing cancer patient population and increased prevalence of diseases are the key market drivers enhancing market growth.

Microbial Products Market Overview

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

April 2024
MicroHarvest, a German biotech business, has collaborated with VEGDOG, an animal-free pet food supplier, to launch the first-ever microbial protein dog treat.
The new treat will be offered on May 6 at the 2024 Pet Food Forum Europe, which will be held in Nuremberg, Germany, during Interzoo Europe.
The VEGDOG Pure Bites snack, which the business claims is a first for Europe's dog food industry, blends MicroHarvest's innovative microbial protein with potato and apple pomace. Its hypoallergenic qualities make it ideal for dogs who cannot accept standard protein sources. MicroHarvest claims that its high tolerance and digestion, as well as its excellent flavor, make it the best option for dogs with severe intolerances and allergies.
"Our goal at VEGDOG is to show dog owners that they do not have to rely on meat-based products to feed their pets," said Tessa Zaune-Figlar, VEGDOG founder and CEO. "With this modern approach and our high-quality, healthy, and delicious products, we were able to pioneer a new market." We are starting a new chapter by cooperating with our partner MicroHarvest to bring to market a potential snack that exhibits our capacity to innovate."
With global protein demand expected to increase by 50% by 2050, MicroHarvest can produce tons of high-quality microbial protein ingredients in just 24 hours, providing a highly scalable and consistent protein solution, according to the company.
"We are constantly looking for innovative protein sources that benefit both our dogs and the environment," stated Dr. Carla Steffen, VEGDOG's director of research and development. "We place a great value on developing our goods using scientific facts. MicroHarvest's microbial protein has been shown to be highly digestible, tasty, and sustainable, therefore it meets all of these criteria.
Fermented microbial proteins, like protein sources from algae, insects, and cell cultures, are more sustainable than animals since they use less land, water, feed, and other resources. Microbial proteins may use less resources than soy and other plant-based proteins.

Microbial Products Market Trends

  • Growing awareness of the value of microbe-based goods is driving the market growth

Market CAGR for microbial products is driven by the significant increase in awareness worldwide. Human illness diagnosis is the primary use of microbial identification. It provides trustworthy findings in a short period, which aids in the timely implementation of therapeutic options. Particularly useful in regions with insufficient healthcare infrastructure, microbial identification products can aid in controlling infectious diseases. Furthermore, the rising incidence of serious diseases like cancer will spur business development in the next years. The production of enzymes for end-use industries like food preservation, leather, and paper is also anticipated to fuel the market's growth over the next few years.

Additionally, the increasing need for microbiological diagnostics. Natural compounds from microbes have had far-reaching effects on human, plant, and animal life, making them a prospective source. More studies show the positive effects of using natural chemicals produced by microorganisms in these industries. Primary metabolites such as amino acids, enzymes, vitamins, organic acids, and alcohol are used in the food and beverage industry and the biotransformation of raw materials. The majority of microorganisms' organic components come from plant or tissue extraction. The biopharmaceutical industry relies heavily on them because of their proven effectiveness in reducing infectious disease prevalence in humans and animals. Nevertheless, there are obstacles, such as the need to keep large numbers of active bacteria on seeds throughout the seed treatment process and the need for technological advances in microbial inoculants. The need to feed a burgeoning  population that is expanding exponentially, the desire for ecologically friendly agricultural practises, and the general public's growing awareness about environmental safety are some of the main drivers of the agricultural microbial sector.

For instance, topline results from the Phase 3 EMBARK trial of XTANDI® (enzalutamide) in men with high-risk biochemical recurrence (BCR) of non-metastatic hormone-sensitive prostate cancer (nmHSPC, also called non-metastatic castration-sensitive prostate cancer or nmCSPC) were announced by Pfizer Inc. and Astellas Pharma Inc. As a result, the demand for microbial products is anticipated to increase throughout the projection period due to rising awareness. Thus, the driving factor is microbial products market revenue.

Microbial Products Market Segment Insights

Microbial Products Type Insights

The  microbial products market segmentation, based on type, includes enzymes, polysaccharides, nutrients, chemotherapeutic agents, antibiotics, and vaccines. In 2022, the enzymes segment led the microbial products market in revenue because it speeds up the digestive and absorption processes, which may help people consume fewer calories and shed excess weight.

Microbial Products Source Insights

The  microbial products market segmentation, based on source, includes bacterial, viral, and fungi. The bacterial segment is expected to develop at a CAGR of 6.20% over the projected period, making up the largest market share due to the extremophile strains collected from a wide range of environments, microbial genomic DNA from strains that possibly enhanced by the use of the polymerase chain reaction (PCR) technique, methicillin-resistant and -sensitive research materials, quality control organisms for commercial identification systems, and bacterial cultures are all routinely used in laboratories and manufacturing settings.

Figure 1  Microbial Products Market by Source, 2022 & 2032 (USD Billion)Microbial Products Market by Source, 2022 & 2032 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Microbial Products Application Insights

The  microbial products market segmentation, based on application, includes pharmaceutical, diagnostic, and biotechnology. The segment with the largest market share in biotechnology is expected to grow fastest at a CAGR of 6.20% over the next several years due to the factors that can be traced back to the sophisticated engineering employed in biotechnology to increase the production of microbial products by means such as the introduction of mutations into an organism and the amplification of genes with plasmids.

Microbial Products End-Users Insights

The  microbial products market segmentation, based on end-users, includes pharmaceutical industries, biotechnological industries, hospitals & clinics, diagnostic labs, research, and academics. The hospitals & clinics' top seller is expected to grow fastest at a CAGR of 6.20% in the future because of a rise in disorder incidence.

 Microbial Products Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American microbial products market will dominate due to technological progress, and the rate at which regulators approve identical candidates is rising.

Further, the major countries studied in the market report are The US, Canada, German, France, the U.K, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2  Microbial Products Market Share By Region 2022 (USD Billion)MICROBIAL PRODUCTS MARKET SHARE BY REGION 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe’s microbial products market accounts for the second-largest market share because of the increasing occurrence of novel infectious diseases and the significance of clinical goods based on microbes. Further, the German microbial products market held the largest market share, and the UK microbial products market was the fastest-growing market in the European region.

The Asia-Pacific microbial products market is expected to grow at the fastest CAGR from 2024 to 2032 due to an increase in the need for everything from immunizations to amino acids and population growth. In addition, the rising government awareness in the region has increased the need for clinical labs. Moreover, China’s microbial products market held the largest market share, and the Indian microbial products market was the fastest-growing market in the Asia-Pacific region.

Microbial Products Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development to expand their product lines, which will help the microbial products market grow even more. There are some strategies for action that market participants are implementing to increase their presence around the world's  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the microbial products industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics manufacturer use in the  microbial products industry to benefit clients and increase the market sector. In recent years, the microbial products industry has offered some of the most significant technological advancements. Major players in the microbial products market, including Amgen Inc., Merck & Co. Inc., VALENT Biosciences Corp., GlaxoSmithKline plc., Pfizer Inc., BIOMÉRIEUX SA, Ajinomoto Co. Inc., SANOFI S.A, Novartis AG, NOVADIGM Therapeutics, Kyowa Hakko Bio Co. Ltd., and others, are attempting to increase market demand by investing in research and development operations.

Amgen's mission is to find, create, manufacture, and distribute novel human medicines to benefit patients with life-threatening illnesses. Part of the plan is to use cutting-edge human genetics and others. Amgen employs its expertise to target areas with significant medical needs and to develop treatments that drastically enhance patients' quality of life. Amgen has been a leader in the biotechnology industry since its founding in 1980. The company has treated millions of patients worldwide and is working on several innovative medications that could revolutionize the industry. Amgen is included in the Dow Jones Industrial Average and the Nasdaq-100 indices. Amgen was designated one of Forbes' "World's Best Employers" and one of Barron's "America's 100 Most Sustainable Companies" in 2022. In May 2023, Amgen and TScan Therapeutics, Inc. established a multi-year agreement to identify the antigens identified by T cells in Crohn's disease patients using TScan's unique target identification technology, TargetScan.

Merck, or MSD outside of North America, has one common goal to save and improve people's lives worldwide by applying cutting-edge research. We have given people a reason to believe in the future for more than 130 years, thanks to the creation of life-saving medicines and vaccinations. Today, we are at the vanguard of research to bring you innovative health solutions that improve the treatment and prevention of illness in humans and other animals. Tomorrow, we hope to be the world's preeminent research-intensive biopharmaceutical firm. Every day, we fight to create a secure future that is both sustainable and healthy for all communities and individuals worldwide by cultivating a diverse and inclusive  workforce and acting ethically. In April 2023, Moderna, Inc., the world's leading developer of messenger RNA (mRNA) therapeutics and vaccines, Merck, or MSD in other parts of the world, presented the first detailed results from their Phase 2b KEYNOTE-942/mRNA-4157-P201 trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck's anti- I. 

Key Companies in the Microbial Products Market include

  • Amgen Inc.

  • Merck & Co. Inc.

  • VALENT Biosciences Corp.

  • GlaxoSmithKline plc.

  • Pfizer Inc.


  • Ajinomoto Co. Inc.


  • Novartis AG

  • NOVADIGM Therapeutics

  • Kyowa Hakko Bio Co.

Microbial Products Industry Developments

April 2023: Amgen collaborators at the Association of Black Cardiologists (ABC) and Morehouse School of Medicine (MSM) have started the African American Heart Study to evaluate the association between Lp (a) and atherosclerotic cardiovascular disease (ASCVD). Five thousand African Americans from the United States will participate in the study. Atherosclerotic cardiovascular disease (ASCVD) involves cardiac arrest and cerebrovascular accident, both caused by cholesterol plaque in the arteries.

March 2023: GSK plc and SCYNEXIS, Inc. have purchased the rights to commercialize Brexafemme worldwide. The FDA has approved Brexafemme (ibrexafungerp tablets) to treat and prevent vulvovaginal candidiasis (VVC) in the United States. 

Microbial Products Market Segmentation

Microbial Products Type Outlook

  • Enzymes

  • Polysaccharides

  • Nutrients

  • Chemotherapeutic Agents

  • Antibiotics

  • Vaccines

Microbial Products Source Outlook

  • Bacterial

  • Viral

  • Fungi

Microbial Products Applications Outlook

  • Pharmaceutical

  • Diagnostic

  • Biotechnology

Microbial Products End-Users Outlook

  • Pharmaceutical Industries

  • Biotechnological Industries

  • Hospitals and Clinics

  • Diagnostic Labs

  • Research

  • Academics

Microbial Products Regional Outlook

  • North America

    • US

    • Canada

  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe

  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Australia

    • Rest of Asia-Pacific

  • Rest of the World

    • Middle East

    • Africa

    • Latin America

Microbial Products Report Scope
Report Attribute/Metric Details
Market Size 2023 USD 1.59 Billion
Market Size 2024 USD 1.69 Billion
Market Size 2032 USD 2.58 Billion
Compound Annual Growth Rate (CAGR) 5.44% (2024-2032)
Base Year 2023
Market Forecast Period 2024-2032
Historical Data 2018- 2022
Market Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
Segments Covered Type, Source, Applications, End-Users, and Region
Geographies Covered North America, Europe, Asia Pacific, Aircraft Type, and the Rest of the World
Countries Covered The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled Amgen Inc., Merck & Co. Inc., VALENT Biosciences Corp., GlaxoSmithKline plc., Pfizer Inc., BIOMÉRIEUX SA, Ajinomoto Co. Inc., SANOFI S.A, Novartis AG, NOVADIGM Therapeutics, Kyowa Hakko Bio Co. Ltd.
Key Market Opportunities Advanced Treatment and Significance in the medical field
Key Market Dynamics Rising need for microbiological diagnosticsA rise in interest in dietary supplements such as vitamins and calcium tablets

Frequently Asked Questions (FAQ) :

The  microbial products market size was valued at USD 1.59 Billion in 2023.

The  market is projected to grow at a CAGR of 5.44% during the forecast period, 2024-2032.

North America had the largest share of the  market.

The key players in the market are Amgen Inc., Merck & Co. Inc., VALENT Biosciences Corp., GlaxoSmithKline plc, Pfizer Inc., BIOMÉRIEUX SA, Ajinomoto Co. Inc., SANOFI S.A, Novartis AG, NOVADIGM Therapeutics, and Kyowa Hakko Bio Co. Ltd.

The enzymes type category dominated the market in 2022.

Biotechnology had the largest share of the market.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.